文献速递流行病学与生物统计基础与转化研究临床试验与 GCP

脓毒症新型临床表型的推导、验证及潜在治疗意义

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.
PubMed 文献 · JAMA · 2019-01-01

该研究基于宾夕法尼亚州12家医院2010至2012年收治的20189例脓毒症患者数据,利用共识k均值聚类从29个变量中推导出α、β、γ、δ四种临床表型,并在验证队列、前瞻性肺炎脓毒症队列及3项随机临床试验中评估其可重复性、与宿主反应生物标志物及临床结局的相关性。四种表型28天死亡率分别为α型5%、β型13%、γ型24%、δ型40%,δ型最高(P < .001)。模拟提示表型频率变化可显著改变试验结果,进一步研究需确定其在临床实践和试验设计中的价值。

要点

  • 基于29个变量聚类推导出α、β、γ、δ四种脓毒症临床表型,各表型宿主反应生物标志物模式存在一致差异。
  • 推导队列28天累积死亡率:α型5%、β型13%、γ型24%、δ型40%,δ型在全部队列和试验中28天及365天死亡率最高(P < .001)。
  • 模拟模型中改变试验内表型频率可显著改变结果,如早期目标导向治疗试验从获益概率>33%变为受害概率>60%。

核心结论

  • 在脓毒症患者的回顾性数据分析中识别出4种与宿主反应模式和临床结局相关的临床表型,模拟提示这些表型可能有助于理解治疗效应的异质性。
  • 确定这些表型在临床护理以及指导试验设计和解读中的效用仍需进一步研究。

研究设计与样本

  • 回顾性分析,使用统计、机器学习和模拟工具。
  • 推导队列为2010至2012年在12家宾夕法尼亚州医院就诊后6小时内符合Sepsis-3标准的20189例患者(16552例唯一患者),对29个变量应用共识k均值聚类。
  • 验证数据库为2013至2014年数据(总计43086例患者,31160例唯一患者),另在前瞻性肺炎所致脓毒症队列(n=583)和3项脓毒症随机临床试验(n=4737)中评估。

主要发现

  • 推导队列患者平均年龄64岁(SD 17),男性10022例(50%),平均24小时最大SOFA评分3.9(SD 2.4)。
  • 验证队列患者平均年龄67岁(SD 17),男性21993例(51%),平均24小时最大SOFA评分3.6(SD 2.0)。
  • α表型最常见(n=6625;33%),血管升压药使用最低;β表型(n=5512;27%)患者年龄更大、慢性病和肾功能不全更多;γ表型(n=5385;27%)炎症和肺功能障碍更多;δ表型(n=2667;13%)肝功能障碍和脓毒性休克更多。
  • 推导队列28天累积死亡率:α表型5691例唯一患者中287例死亡(5%);β表型4420例中561例(13%);γ表型4318例中1031例(24%);δ表型2223例中897例(40%)。
  • 在所有队列和试验中,δ表型28天和365天死亡率高于其他3种表型(P < .001);模拟模型中报告获益、受害或无效果的随机临床试验比例变化显著,例如早期目标导向治疗试验中表型频率变化使结果从获益概率>33%变为受害概率>60%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出确定这些表型在临床护理以及指导试验设计和解读中的效用仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sepsis is a heterogeneous syndrome. Identification of distinct clinical phenotypes may allow more precise therapy and improve care. OBJECTIVE: To derive sepsis phenotypes from clinical data, determine their reproducibility and correlation with host-response biomarkers and clinical outcomes, and assess the potential causal relationship with results from randomized clinical trials (RCTs). DESIGN, SETTINGS, AND PARTICIPANTS: Retrospective analysis of data sets using statistical, machine learning, and simulation tools. Phenotypes were derived among 20 189 total patients (16 552 unique patients) who met Sepsis-3 criteria within 6 hours of hospital presentation at 12 Pennsylvania hospitals (2010-2012) using consensus k means clustering applied to 29 variables. Reproducibility and correlation with biological parameters and clinical outcomes were assessed in a second database (2013-2014; n = 43 086 total patients and n = 31 160 unique patients), in a prospective cohort study of sepsis due to pneumonia (n = 583), and in 3 sepsis RCTs (n = 4737). EXPOSURES: All clinical and laboratory variables in the electronic health record. MAIN OUTCOMES AND MEASURES: Derived phenotype (α, β, γ, and δ) frequency, host-response biomarkers, 28-day and 365-day mortality, and RCT simulation outputs. RESULTS: The derivation cohort included 20 189 patients with sepsis (mean age, 64 [SD, 17] years; 10 022 [50%] male; mean maximum 24-hour Sequential Organ Failure Assessment [SOFA] score, 3.9 [SD, 2.4]). The validation cohort included 43 086 patients (mean age, 67 [SD, 17] years; 21 993 [51%] male; mean maximum 24-hour SOFA score, 3.6 [SD, 2.0]). Of the 4 derived phenotypes, the α phenotype was the most common (n = 6625; 33%) and included patients with the lowest administration of a vasopressor; in the β phenotype (n = 5512; 27%), patients were older and had more chronic illness and renal dysfunction; in the γ phenotype (n = 5385; 27%), patients had more inflammation and pulmonary dysfunction; and in the δ phenotype (n = 2667; 13%), patients had more liver dysfunction and septic shock. Phenotype distributions were similar in the validation cohort. There were consistent differences in biomarker patterns by phenotype. In the derivation cohort, cumulative 28-day mortality was 287 deaths of 5691 unique patients (5%) for the α phenotype; 561 of 4420 (13%) for the β phenotype; 1031 of 4318 (24%) for the γ phenotype; and 897 of 2223 (40%) for the δ phenotype. Across all cohorts and trials, 28-day and 365-day mortality were highest among the δ phenotype vs the other 3 phenotypes (P < .001). In simulation models, the proportion of RCTs reporting benefit, harm, or no effect changed considerably (eg, varying the phenotype frequencies within an RCT of early goal-directed therapy changed the results from >33% chance of benefit to >60% chance of harm). CONCLUSIONS AND RELEVANCE: In this retrospective analysis of data sets from patients with sepsis, 4 clinical phenotypes were identified that correlated with host-response patterns and clinical outcomes, and simulations suggested these phenotypes may help in understanding heterogeneity of treatment effects. Further research is needed to determine the utility of these phenotypes in clinical care and for informing trial design and interpretation.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Seymour CW, Kennedy JN, Wang S, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019. PMID: 31104070. doi:10.1001/jama.2019.5791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。